Clinical trials in Freiburg Im Breisgau – page 22

529 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Freiburg Im Breisgau at a glance

529

clinical trials

Research sites1

Quick filters

529 trials in Freiburg Im Breisgau

Open in trial search

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:ADMILPARANT
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Dermatitis atopic

Not yet recruiting

Study of Lebrikizumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis to Understand How the Medicine Works

Registered drugNo placebo

Study of Lebrikizumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis to Understand How the Medicine Works

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:University Of Michigan

Contact Research Centre

Axial spondyloarthritis+3

Not yet recruiting

Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa

Registered drugNo placebo

Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bimekizumab
Sponsor:UCB Biopharma

Contact Research Centre

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Rheumatoid arthritis+1

Not yet recruiting

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

HIV infection

Not yet recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bictegravir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Glioma

Not yet recruiting

Study of L19TNF and Lomustine for Patients with Recurrent or Progressive Glioblastoma

Registered drugNo placebo

Study of L19TNF and Lomustine for Patients with Recurrent or Progressive Glioblastoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:Philogen S.p.A.

Contact Research Centre

Pancreatic carcinoma metastatic

Not yet recruiting

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:University Of Cologne

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Freiburg Im Breisgau

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer, non-small cell lung cancer, and colon cancer treatments. Studies evaluating new therapeutic approaches for both early-stage and advanced cancers.

Breast Cancer Therapy Optimization
Advanced Lung Cancer Treatments
Gastrointestinal Cancer Research

Emphasis on targeted therapies and combination treatments to improve patient outcomes.

02 Autoimmune Conditions

Research into treatments for psoriatic arthritis, rheumatoid arthritis, and Sjögren's disease. Studies evaluating novel biologics and targeted therapies.

Inflammatory Arthritis Management
Autoimmune Disease Therapeutics
Novel Treatment Approaches

Focus on improving disease control and quality of life for patients with chronic autoimmune conditions.

03 Rare Diseases

Clinical investigations of treatments for spinal muscular atrophy, sickle cell disease, and primary sclerosing cholangitis. Studies aimed at developing innovative therapies.

Genetic Disease Treatments
Blood Disorders
Pediatric Rare Diseases

Dedicated to finding breakthrough treatments for challenging rare conditions.

Back to Germany All countries